Abstract
The use of SGLT2 inhibitors, beyond present guideline-directed medical therapy for patients with type 2 diabetes, chronic kidney disease, high atherosclerotic cardiovascular risk and heart failure, may in the future become a significant addition to the treatment of patients with acute myocardial infarction. Ongoing studies, including the PREDOMINANCE trial, may prove beneficial with this class of agents, already demonstrated to improve outcomes in a wide range of patients, with and without type 2 diabetes. Cardiovascular specialists would benefit from increasing their familiarity with this proven therapeutic class in patients with cardiometabolic and cardiovascular disease and increase their utilization in appropriate patients.